DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
SGI-110 is an investigational drug.
There have been 30 clinical trials for SGI-110. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Preleukemia. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are twenty US patents protecting this investigational drug and one hundred and fifty-four international patents.
Recent Clinical Trials for SGI-110
|Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma||National Cancer Institute (NCI)||Phase 2|
|A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1||Astex Pharmaceuticals, Inc.||Phase 2|
|A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1||Bristol-Myers Squibb||Phase 2|
Top disease conditions for SGI-110
Top clinical trial sponsors for SGI-110
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGI-110||Try Before You Buy||Using DNA methyltransferase inhibitors to treat calcific aorta valve disease||Mayo Foundation for Medical Education and Research (Rochester, MN)||Try Before You Buy|
|SGI-110||Try Before You Buy||Nucleotides for the treatment of liver cancer||IDENIX PHARMACEUTICALS LLC (Cambridge, MA)||Try Before You Buy|
|SGI-110||Try Before You Buy||Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer||UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD)||Try Before You Buy|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SGI-110||Australia||AU2014354775||2033-11-27||Try Before You Buy|
|SGI-110||Brazil||BR112016011949||2033-11-27||Try Before You Buy|
|SGI-110||Canada||CA2931458||2033-11-27||Try Before You Buy|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|